RBC Capital Remains Bullish on Viridian Therapeutics (VRDN) Following Q3 2025 Results

With significant upside potential, Viridian Therapeutics, Inc. (NASDAQ:VRDN) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts.

On November 6, 2025, RBC Capital raised its price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) from $41 to $45, while maintaining an “Outperform” rating. The investment firm’s bullish stance stemmed from clear visibility toward profitability, seen through its increased cash position of $888 million, thanks to financing deals, including $55 million from DRI royalty financing, a $70 million upfront Japan licensing agreement, a $289 million follow-on offering, and access to a $300 million credit facility.

Furthermore, Viridian Therapeutics, Inc. (NASDAQ:VRDN) has completed key patient enrollments in its late-stage clinical studies. Readouts for active and chronic Thyroid Eye Disease (TED) are expected in Q1 and Q2 2026, respectively, driving the investment firm’s bullish stance.

Meanwhile, Viridian Therapeutics, Inc. (NASDAQ:VRDN) reported Q3 2025 results on the previous day. The company closed the quarter with $490.9 million in cash on hand. The cash position further increased as a result of the financing deals. The quarter also marked a significant increase in R&D expenses, which grew from $69.2 million in the same quarter last year to $86.3 million.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) is focused on the development and commercialization of therapies for rare diseases.

While we acknowledge the potential of VRDN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 7 Best Oil and Gas Penny Stocks to Buy According to Analysts and Billionaire Jacob Rothschild’s RIT Capital Partners: 9 Stocks with Huge Upside Potential.

Disclosure: None.